IP Library Granted Patent US 11,884,926
Granted Patent B2
US 11,884,926 · App. 16/966,504 · Granted Jan 30, 2024

Campaign-ready series of recombinant adeno-associated virus (rAAV) complementing plasmids

Inventors: Terence Flotte (Holden, MA); Qiushi Tang (Worcester, MA); Allison Keeler-Klunk (Sutton, MA); Qin Su (Westborough, MA)
Assignee: University of Massachusetts
C12N15/70C12N7/00C12N2750/14143C12N2750/14151C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,926
App. No.
16/966,504
Granted
Jan 30, 2024
Kind
B2
Abstract

In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 10 13 to 10 16 viral particles.)

Claims (26)

1. A recombinant adeno-associated virus (rAAV) production system comprising:

(i) a first vector comprising the nucleic acid sequence set forth in any one of SEQ ID NOs: 1-9;

and,

(ii) a second vector comprising one or more nucleic acids encoding an expression cassette comprising a transgene flanked by adeno-associated virus inverted terminal repeat (ITR) sequences.

2. The rAAV production system of claim 1 , wherein the adeno-associated virus inverted terminal repeat (ITR) sequences are AAV2 ITRs.

3. The rAAV production system of claim 1 , wherein the transgene is a protein or an inhibitory nucleic acid, optionally wherein the inhibitory nucleic acid is dsRNA, siRNA, miRNA, or amiRNA.

4. The rAAV production system of claim 1 , wherein the expression cassette further comprises a promoter operably linked to the transgene, optionally wherein the promoter is a H1, U6, CB, CBA, CB6, Desmin, CMV, AAT, or MHK promoter.

5. The rAAV production system of claim 1 , further comprising a host cell.

6. An isolated nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 1-9.

7. A method for producing a recombinant adeno-associated virus (rAAV), the method comprising introducing the rAAV production system of claim 1 into a host cell that expresses an Ad-Ela helper function.

8. The method of claim 7 , wherein the first vector and second vector of the rAAV production system are introduced into the host cell in (i) a single transfection reaction or (ii) separate transfection reactions.

9. The method of claim 7 , further comprising the step of culturing the cells after introduction of the rAAV production system.

10. A method for producing a recombinant adeno-associated virus (rAAV), the method comprising:

(i) introducing the isolated nucleic acid of claim 6 into a host cell that expresses an Ad-Ela helper function; and

(ii) introducing a vector comprising one or more nucleic acids encoding an expression cassette comprising a transgene flanked by adeno-associated virus inverted terminal repeat (ITR) sequences.

11. The method of claim 10 , wherein the host cell is a mammalian cell.

12. The method of claim 10 , wherein the isolated nucleic acid and the vector are introduced into the host cell in (i) a single transfection reaction or (ii) separate transfection reactions.

13. The method of claim 10 , further comprising the step of culturing the cells after the introduction of the nucleic acid and the vector.

14. An apparatus for production of recombinant adeno-associated virus (rAAV) particles, the apparatus comprising:

(i) a container housing the rAAV production system of claim 1 ; and,

(ii) a population of host cells,

wherein the rAAV production system and the host cells are suspended in a cell culture medium.

15. The rAAV production system of claim 5 , wherein the host cell is a mammalian cell.

16. The method of claim 9 , wherein the culturing occurs in the presence of an antibiotic cognate to the antibiotic-resistance gene of the first vector.

17. The method of claim 10 , wherein the mammalian cell is a HEK293 cell, HEK293T cell, or a CHO cell.

18. The method of claim 13 , wherein the culturing occurs in the presence of an antibiotic cognate to the antibiotic-resistance gene of the first vector.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2020
From: FLOTTE, TERENCE; TANG, QIUSHI; KEELER-KLUNK, ALLISON; SU, QIN
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 054206/0140 →
CONFIRMATORY LICENSE Recorded Aug 5, 2020
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053402/0356 →
Continuity (2)
Provisional Application 62625644 · Feb 2, 2018
Related Publication 20210047650A1 · Feb 18, 2021